The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET)
Status:
Completed
Trial end date:
2008-01-22
Target enrollment:
Participant gender:
Summary
Age related differences in response to a drug could arise from variation in pharmacokinetic
(PK) and/or pharmacodynamic (PD) profiles between age groups. Whilst the efficacy and safety
profile of anagrelide is well established through a well-documented clinical trial programme
in patients of all ages, no formal studies have been carried out to investigate whether the
PK profile of anagrelide and its metabolites is altered with age.
This study is designed to allow comparisons to be made in terms of pharmacokinetics of
anagrelide and its metabolites between elderly (≥ 65 years) and young (18-50 years) ET
patients